Brook Jackson, a regional director, was fired from her clinical trial auditor work after raising her voice against the system. Here’s all you need to know about the case.
According to a regional director who worked in Vestavia Research Group, it manipulated data, unblinded patients, used insufficiently trained staff, and was reluctant to follow up on adverse events in Pfizer’s crucial phase III study.
The number of issues discovered by quality control staff was overwhelming.
Experts, on the other hand, have given their opinions on the situation. Brook’s assertion is described as “vague and imprecise.”
Brook Jackson, the regional director, sent a complaint to the US Food and Drug Administration after repeatedly informing Ventavia of the concerns (FDA). Later that day, Ventavia fired her. Hundreds of internal corporate papers, pictures, audio recordings, and emails have been handed to the BMJ by Jackson.
Pfizer vaccine clinical trial irregularities: “the regional director, Brook Jackson, emailed a complaint to the US Food and Drug Administration (FDA). Ventavia fired her later the same day” https://t.co/Bf85HWhWHl
— Alex Holcombe (@ceptional) November 3, 2021
Who Is Brook Jackson?
Brook Jackson was fired from her job as a clinical trial auditor after “raising her voice against the system.”
Jackson was a qualified clinical trial auditor who had previously worked as a director of operations. She had more than 15 years of expertise in clinical research coordination and administration when he joined Ventavia.
Pfizer Whistleblower Fired By Ventavia – What Happened?
Ventavia was contracted by Pfizer Whistleblower, as a research subcontractor on four other vaccination clinical studies, including the COVID-19 vaccine in children and young people, pregnant women, and a booster dosage.
Jackson took images on her phone late one night to document a number of events. In one photo, study participants’ identifying numbers were written on their left out in the open on vaccination package materials, potentially unblinding them.
Following that, Jackon’s position was terminated. She stated that it was the first time in her 20-year research career that she had been dismissed.
Moreover, Jackson, who spoke to The BMJ, drug assignment confirmation printouts were left in participants’ files, available to (theoretically) blinded employees.
Later on, quality assurance checklists were revised with instructions for staff to delete medication assignments from charts as a remedial measure made in September, two months into trial recruitment, and with about 1000 patients having been recruited.
When the trial documentation was examined for quality control, the firm was unable to quantify the types and quantity of mistakes detected.
“ After repeatedly notifying Ventavia of these problems, the regional director, Brook Jackson, emailed a complaint to the US (FDA). Ventavia fired her later the same day. Jackson has provided BMJ with dozens of internal company documents, photos, audio recordings, and emails.
— Randy Hillier (@randyhillier) November 2, 2021